Operate an online healthcare platform in China. Provide a wide range of pharmaceutical products, including OTC and prescription drugs. Now — the numbers.
This is an established company with proven profits.
Average growth of 24% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $7.1B would still be left in the vault — a solid cushion for hard times.
The market pays 19.8× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 24% a year on average.
There is $7.2B in the vault; even if every debt were paid off, $7.1B would remain.
Since the drop from its peak, buyer appetite hasn’t come back.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.